Loading
Alnylam Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 12 May 2025.
Alnylam Pharmaceuticals, Inc.: what insiders have been doing
Headquartered in Cambridge, United States, Alnylam Pharmaceuticals, Inc. belongs to the Healthcare & Pharma sector and traces its origins to 2002. Filings by its managers are published through SEC (Form 4). Between 18 October 2025 and 18 October 2026, 17 insiders published 68 filings.
Only sales appear on the open market, 31 sales in all totalling €7.2M, filed by 8 insiders. The largest single trade was a sale of €1.8M by Greenstreet Yvonne, published on 17 February 2026.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Across the 5,814 companies tracked on its exchange, the median is 19 filings; at 68 filings, this issuer sits above that mark. Since 2016, the database holds 2 purchases and 190 sales by insiders of the company. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 3.71 bn USD and net income of 313.7 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
358
Thresholds
n/a
Buy Volume
€8,260
2 ops. · all time
Sell Volume
€54M
190 ops. · all time
Who traded when
BuySaleGarg Pushkal37 sales
Fitzgerald Kevin Joseph29 sales
Yvonne Greenstreet25 sales
Poulton Jeffrey V.22 sales
Tanguler Tolga16 sales
Melissa McLaughlin14 sales
+3 other insiders
Since the insiders bought
- +9.2%Entry US$266.86 · Close at T+365 US$291.48
- -36.7%Entry US$67.51 · Close at T+365 US$42.76
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Alnylam Pharmaceuticals, Inc. Buy (bullish), based on 26 analysts. Average price target: US$371.35.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 11,690 of 24,148 companies
52.4
score / 100
Value28
Quality76
FCF yld1.4%
Earn yld0.9%
EV/EBITDA55.9x
ROE97%
Gross mgn82%
Net mgn8.4%
Debt/EBITDA2.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$254.07
Analyst consensus
26 analystsBuy
US$256.00Target US$371.35(+46%)US$536.00
Income statement
RevenueUS$3.7B
Gross profitUS$3B82% margin
EBITDAUS$631.4M17% margin
Net incomeUS$313.7M16.1% margin
Valuation
PER (trailing)44.4x
PER (forward)20.4x
P/Book25.1x
Beta0.30
Balance sheet & cash
Market capUS$34B
Total debtUS$1.3B
Free Cash FlowUS$465.4M
Debt / Equity221%
Profitability & ownership
ROE96.6%
ROA12.3%
% insiders0.2%
% institutions101.7%
Last declaration on 6 October 2026
Declarations358 total
1,758 shares@ US$226.880.0012% mcap50.0% of flowCommon StockSEC:0001178670-26-000068:0
1,758 shares@ US$226.88410.0012% mcap100.0% of flowCommonSEC144:0001959173-26-007216
107 shares0Common StockSEC:0001178670-26-000065:0
1,175 shares@ US$298.910.0011% mcap5.9% of flowCommon StockSEC:0001178670-26-000048:2
17 shares@ US$302.650.0000% mcap0.1% of flowCommon StockSEC:0001178670-26-000048:5
921 shares@ US$297.710.0008% mcap4.6% of flowCommon StockSEC:0001178670-26-000048:1
1,222 shares@ US$299.870.0011% mcap6.2% of flowCommon StockSEC:0001178670-26-000048:3
495 shares@ US$300.720.0005% mcap2.5% of flowCommon StockSEC:0001178670-26-000048:4
3,830 shares0Common StockSEC:0001178670-26-000048:0
671 shares0Common StockSEC:0001178670-26-000034:0
671 shares0Common StockSEC:0001178670-26-000035:0
671 shares0Common StockSEC:0001178670-26-000036:0
671 shares0Common StockSEC:0001178670-26-000037:0
671 shares0Common StockSEC:0001178670-26-000038:0
671 shares0Common StockSEC:0001178670-26-000039:0
671 shares0Common StockSEC:0001178670-26-000040:0
838 shares0Common StockSEC:0001178670-26-000041:0
671 shares0Common StockSEC:0001178670-26-000042:0
11,250 shares@ US$70.200.0024% mcap17.3% of flowCommon StockSEC:0001178670-26-000017:0
224 shares@ US$321.640.0002% mcap5.7% of flowCommon StockSEC:0001178670-26-000014:5
8 shares@ US$325.490.0000% mcap0.2% of flowCommon StockSEC:0001178670-26-000014:8
56 shares@ US$320.140.0001% mcap1.4% of flowCommon StockSEC:0001178670-26-000014:9
909 shares@ US$329.760.0009% mcap23.5% of flowCommon StockSEC:0001178670-26-000014:10
81 shares@ US$323.640.0001% mcap2.1% of flowCommon StockSEC:0001178670-26-000014:7
293 shares@ US$331.890.0003% mcap7.6% of flowCommon StockSEC:0001178670-26-000014:12
25 of 358 declarations
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. (ticker: ALNY) is a U.S.-listed biopharmaceutical company traded on the NASDAQ in the United States, with corporate headquarters in Cambridge, Massachusetts. Founded in 2002 by a group of leading scientists, Alnylam became the pioneer of RNA interference (RNAi) therapeutics, a gene-silencing approach designed to reduce the production of disease-causing proteins. For international equity investors, the company’s appeal lies not just in a single drug franchise but in a proprietary technology platform that has moved from scientific promise to meaningful commercial scale.
Alnylam’s core business is the discovery, development, manufacturing and commercialization of siRNA-based medicines for serious and often rare diseases with substantial unmet need. The company’s marketed portfolio now centers on four key products: AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran) and OXLUMO (lumasiran). These therapies address important disease areas including transthyretin amyloidosis (ATTR), hereditary ATTR polyneuropathy, acute hepatic porphyria and primary hyperoxaluria type 1. In March 2025, Alnylam also secured FDA approval for Qfitlia (fitusiran), its sixth Alnylam-discovered RNAi therapeutic approved in the United States, indicated for routine prophylaxis in hemophilia A or B. That approval broadened the company’s reach beyond its established amyloidosis franchise.
Read moreShow less
Competitively, Alnylam holds a leading position in RNAi therapeutics, supported by a long development track record, deep intellectual property, and expertise in oligonucleotide delivery and manufacturing. The company’s scientific differentiation is a key barrier to entry, especially in therapeutic categories where efficacy, durability and convenience matter. Its strongest commercial momentum is currently in ATTR, where AMVUTTRA has become the flagship asset. The drug is now approved in the United States, Europe and Brazil for ATTR cardiomyopathy, helping expand the addressable market and reinforcing Alnylam’s leadership in one of the most attractive rare-disease franchises in biotech.
Geographically, Alnylam is increasingly global. While the United States remains its core market, the company has built a broader international footprint through sequential regulatory approvals and commercialization efforts in Europe and other regions. Recent milestones underscore the transition from development-stage biotech to commercial biotech at scale: FDA approval of AMVUTTRA for ATTR-CM in March 2025, FDA approval of Qfitlia in March 2025, European Commission approval of AMVUTTRA for ATTR-CM in June 2025, and the company’s February 2026 report of nearly $3.0 billion in 2025 net product revenues, alongside first-ever full-year GAAP and non-GAAP profitability. Taken together, these developments highlight a company with strengthening commercial leverage, expanding label breadth and a more mature financial profile.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
